Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsed or Refractory Multiple Myeloma Clear all
Terminated Phase 1Phase 2 Interventional Results available

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

NCT01177683
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Doxorubicin, Bortezomib, Filgrastim
Drug
Lead sponsor
Sherif Farag, MB, BS
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Wyoming, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 24, 2026, 1:54 AM EDT
Approved For Marketing No phase listed Expanded access

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

NCT01632826
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
U.S. locations
25
States / cities
Duarte, California • Greenbrae, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 24, 2026, 1:54 AM EDT
Active, not recruiting Phase 1 Interventional

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT03798678
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Telaglenastat Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Tampa, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
Interventions
Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Redlands, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

NCT00741377
View directory record Official record
Conditions
Multiple Myeloma Bone Disease
Interventions
BHQ880, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 1Phase 2 Interventional

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01464034
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
9
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma

NCT00241371
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Clofarabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Jul 24, 2026, 1:54 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06356571
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Dexamethasone, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT02579824
View directory record Official record
Conditions
Myeloma
Interventions
DS-3032b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jul 24, 2026, 1:54 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

NCT01695590
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PRLX 93936
Drug
Lead sponsor
Prolexys Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 24, 2026, 1:54 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Elranatamab, GM-CSF, DC/MM Fusion Vaccine
Drug · Biological
Lead sponsor
David Avigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
No Longer Available No phase listed Expanded access

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00423826
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Jul 24, 2026, 1:54 AM EDT
Recruiting Phase 2 Interventional

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT06103838
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
18F-fluciclovine injection, 18F-FDG PET/CT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

NCT01583283
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

NCT00017069
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
arsenic trioxide, dexamethasone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 24, 2026, 1:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07479979
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone
Drug · Device
Lead sponsor
Natalie Callander
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 24, 2026, 1:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03333746
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab, Pharmacological Study
Other · Drug · Biological
Lead sponsor
Yvonne Efebera
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 24, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional Results available

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00687674
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, sorafenib tosylate, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 24, 2026, 1:54 AM EDT
Completed Phase 2 Interventional

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00047203
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
alvocidib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 24, 2026, 1:54 AM EDT